Edition:
India

Cellmid Ltd (CDY.AX)

CDY.AX on Australia Stock Exchange

0.10AUD
24 Nov 2020
Change (% chg)

$-0.00 (-4.76%)
Prev Close
$0.10
Open
$0.10
Day's High
$0.10
Day's Low
$0.10
Volume
19,972
Avg. Vol
241,468
52-wk High
$0.49
52-wk Low
$0.08

Latest Key Developments (Source: Significant Developments)

Cellmid Signed Exclusive Agreement With Tru Beauty Concepts
Tuesday, 28 Jul 2020 

July 28 (Reuters) - Cellmid Ltd ::SIGNED EXCLUSIVE DISTRIBUTION AGREEMENT WITH TRU BEAUTY CONCEPTS FOR ÉVOLIS PROFESSIONAL ANTI-AGING HAIR CARE PRODUCTS.DEAL IS EXPECTED TO DELIVER SIGNIFICANT REVENUE GROWTH TO US BUSINESS FROM 2HFY2021.  Full Article

Cellmid Says Revenue For Group In Q4 Was $3.06 Million
Wednesday, 22 Jul 2020 

July 22 (Reuters) - Cellmid Ltd ::CELLMID- REVENUE FOR GROUP IN Q4 FY2020 WAS $3.06 MILLION.  Full Article

Cellmid Says Signed Exclusive Distribution Agreement With Immunodiagnostics, HK
Thursday, 9 Jul 2020 

July 9 (Reuters) - Cellmid Ltd ::SIGNED EXCLUSIVE DISTRIBUTION AGREEMENT WITH IMMUNODIAGNOSTICS, HONG KONG.DEAL ON ENZYME LINKED IMMUNOSORBENT ASSAYS & POINT OF CARE SEROLOGY TEST FOR SARS-COV-2 FOR AUSTRALIA & NZ.  Full Article

Cellmid Expect Consumer Health Sales In FY2020 To Be Similar To FY2019
Tuesday, 16 Jun 2020 

June 16 (Reuters) - Cellmid Ltd ::EXPECT CONSUMER HEALTH SALES IN FY2020 TO BE SIMILAR TO FY2019, IN LINE WITH LATEST VIEW.  Full Article

Cellmid Signed Introducer Agreement With Emergence Technology Pty
Thursday, 4 Jun 2020 

June 4 (Reuters) - Cellmid Ltd ::CELLMID SIGNED INTRODUCER AGREEMENT WITH EMERGENCE TECHNOLOGY PTY LTD.AGREEMENT ALLOWS CELLMID CUSTOMERS ACCESS TO ADDITIONAL SARS-COV-2 TESTS.  Full Article

Cellmid Says Co Raised $6 Million Via Share Placement
Tuesday, 7 Apr 2020 

April 7 (Reuters) - Cellmid Ltd ::RAISED $6 MILLION VIA A SHARE PLACEMENT FROM INSTITUTIONAL AND SOPHISTICATED INVESTORS.PLACEMENT WILL RESULT IN ISSUE OF ABOUT 27.3 MILLION MILLION FULLY PAID ORDINARY SHARES AT 22 CENTS EACH.EXISTING SHAREHOLDERS WILL HAVE OPPORTUNITY TO PARTICIPATE ON SAME TERMS VIA A SHARE PURCHASE PLAN TARGETING AN ADDITIONAL $1.0 MILLION.PROCEEDS RAISED UNDER OFFER TO FUND ROLL OUT OF WONDFO SARS-V-2 DIAGNOSTIC TEST.  Full Article

Cellmid Updates Market On COVID-19 Impact
Friday, 27 Mar 2020 

March 27 (Reuters) - Cellmid Ltd ::PRUDENT TO WITHDRAW PREVIOUS GUIDANCE THAT IT WILL ACHIEVE OPERATIONAL PROFITABILITY FOR ITS CONSUMER BUSINESS BY END OF FY2020.JAPANESE BUSINESS EXPECTED TO DELIVER ON BUDGET FOR SECOND HALF OF 2020 FINANCIAL YEAR.DELIVERY OF CHINESE EXPORT ORDER NOW EXPECTED TO OCCUR IN TWO SPERATE SHIPMENTS IN APRIL AND MAY 2020.OPERATIONAL EXPENDITURE OF CO REDUCED WHERE SENSIBLE.RECENTLY SECURED SUPPLY OF WONDFO COVID-19 RAPID DIAGNOSTIC TEST IN AUSTRALIA.CELLMID-AUSTRALIA PRODUCT LAUNCH PLANNED FOR MARCH IN PRICELINE HAS BEEN DELAYED, WILL START EFFECTING SALES FROM APRIL ONWARDS LOCALLY.WILL SEPARATE LYRAMID INTO WHOLLY INDEPENDENT ENTITY BACKED BY INDEPENDENT FUNDING AND/OR PARTNERSHIP WITH BIOPHARMACEUTICAL CO BY 2020 END.  Full Article

Cellmid Says Consumer Health Sales $2.45 Million For Q2 FY20, Up 19%
Thursday, 30 Jan 2020 

Jan 30 (Reuters) - Cellmid Ltd ::CONSUMER HEALTH SALES FOR Q2 FY2020 $2.45 MILLION, UP 19%.  Full Article

Cellmid Signs Trading Agreement With API/Priceline
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - Cellmid Ltd ::SIGNS TRADING AGREEMENT WITH API/PRICELINE.CONFIRMS GUIDANCE THAT IT IS ON TRACK TO REACH OPERATIONAL PROFITABILITY IN CONSUMER HEALTH BUSINESS IN FY2020.UNIT ENTERED INTO NATIONAL TRADING AGREEMENT WITH API FOR RANGING OF ITS ÉVOLIS PROFESSIONAL ANTI- AGING HAIR CARE PRODUCTS.  Full Article

Cellmid Posts Q1 Sales Of $1.38 Million
Wednesday, 23 Oct 2019 

Oct 23 (Reuters) - Cellmid Ltd ::GENERATED $1.38 MILLION IN SALES IN Q1 FY2020, ON PAR WITH PCP.  Full Article